Stockscreener 앱 받기
3.13
4.86%
-0.16
시간 외 거래:
3.14
0.01
+0.32%
전일 마감가:
$3.29
열려 있는:
$3.28
하루 거래량:
641.97K
Relative Volume:
1.35
시가총액:
$103.98M
수익:
$66.16M
순이익/손실:
$128.94M
주가수익비율:
0.9836
EPS:
3.1823
순현금흐름:
$152.08M
1주 성능:
-6.29%
1개월 성능:
+2.29%
6개월 성능:
+0.97%
1년 성능:
+69.19%
1일 변동 폭
$3.0802
$3.28
1주일 범위
$3.0802
$3.505
52주 변동 폭
$1.77
$4.53
Fortress Biotech Inc Stock (FBIO) Company Profile
명칭
Fortress Biotech Inc
전화
781-652-4500
주소
1111 KANE CONCOURSE, BAY HARBOR ISLANDS, NY
Compare FBIO vs VRTX, REGN, ARGX, RVMD, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
FBIO
Fortress Biotech Inc
|
3.13 | 108.63M | 66.16M | 128.94M | 152.08M | 3.1823 |
VRTX
Vertex Pharmaceuticals Inc
|
477.10 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
762.63 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
853.82 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
187.53 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
316.01 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Fortress Biotech Inc Stock (FBIO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-03-15 | 재개 | ROTH MKM | Buy |
| 2022-08-04 | 개시 | Ladenburg Thalmann | Buy |
| 2020-10-02 | 개시 | The Benchmark Company | Buy |
| 2019-12-18 | 개시 | B. Riley FBR | Buy |
| 2018-02-28 | 개시 | B. Riley FBR, Inc. | Buy |
| 2017-07-11 | 개시 | Rodman & Renshaw | Buy |
| 2017-03-22 | 개시 | JMP Securities | Mkt Outperform |
| 2016-10-03 | 개시 | ROTH Capital | Buy |
모두보기
Fortress Biotech Inc 주식(FBIO)의 최신 뉴스
Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics $130 Million Series B Financing - marketscreener.com
Fortress Biotech Inc (FBIO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Fortress Biotech Inc (FBIO) Balance Sheet - TradingKey
Fortress Biotech Inc (FBIO) Institutional Confidence - TradingKey
Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics’ $130 Million Series B Financing - The Manila Times
FBIO|Fortress Biotech Inc|Price:3.340|Chg%:-0.090 - TradingKey
Fortress Biotech Inc (FBIO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Fortress Biotech Inc (FBIO) Valuation: PE, PB & Fair Value Analysis - TradingKey
Fortress Biotech Inc (FBIO) Income Statement - TradingKey
Fortress Biotech Inc (FBIO) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Fortress Biotech, Inc.9.375% Series A Cumulative Redeemable Perpetual Preferred Stock - TradingView
Fortress Biotech Inc (FBIO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Fortress Biotech Inc (FBIO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Fortress Biotech: Cash Above Market Cap And Royalty Upside Make This A Speculative Buy - Seeking Alpha
Fortress Biotech Preferred Stock (FBIOP) Holds Steady Near Support Amid Low Volume TradingMerger Arbitrage - dars.gov.et
Technical Reactions to FBIOP Trends in Macro Strategies - Stock Traders Daily
$3.74 | Fortress Biotech, Inc. Common Stock (FBIO) Stock Price Today - Binance
Fortress Biotech Achieves 73.6% Return in the Stock Market Over Past Year - MarketsMojo
MSN Money - MSN
CNB0 Bond Coupon Profile — Rate & Payments - TradingView
Crinetics Pharmaceuticals Acquired by Fortress Biotech for $10 Billion - BioBuzz
Fortress Biotech Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock (FBIOP) Q1 2026 Earnings: EPS Misses Estimates Significantly, Stock DeclinesEarnings Weakness Phase - dars.gov.et
Fortress Biotech (FBIO) Edges Lower Amid Quiet Trading, Holds Above Key SupportWeekly Profile - DonanımHaber
Fortress Biotech highlights its biotech portfolio strategy as a Nasdaq-listed micro-cap - Ad Hoc News
Mustang Bio (MBIO) Registration Filing Summary - Quartr
Fortress Biotech Preferred Shares (FBIOP) Slide 1.98% as Support Test ApproachesPut Flow Alert - dars.gov.et
Fortress Biotech focuses on specialty pharma growth and licensing model - Ad Hoc News
Crinetics Pharmaceuticals Acquired by Fortress Biotech for $10 B - GuruFocus
Fortress Biotech (FBIO) Slides 2.14% as Selling Pressure Persists Near Support LevelHigh Dividend Factor - dars.gov.et
Fortress Biotech Inc highlights its specialty pharma model as investors assess long-term prospects - Ad-hoc-news.de
Fortress Biotech, Inc. Actuals & Estimates (NASDAQ:FBIO) - TradingView
Trading the Move, Not the Narrative: (FBIOP) Edition - Stock Traders Daily
FBIO Forecast — Price Target — Prediction for 2027 - TradingView
Price to sales forward of Fortress Biotech, Inc. – NASDAQ:FBIO - TradingView
Form 4 Fortress Biotech Inc For: 24 June By Investing.com - Investing.com Nigeria
Journey Medical (DERM) Stock Draws Fresh Price Target Split After Fortress Valuation Changes - Yahoo Finance
Fortress Biotech (NASDAQ: FBIO) CFO receives 400,000 RSU award - Stock Titan
Enterprise value to revenue forward of Fortress Biotech, Inc. – NASDAQ:FBIO - TradingView
FBIOP Q1 2026 Earnings: Significant EPS Miss Highlights Ongoing Challenges for Fortress BiotechAnalyst Coverage Count - dars.gov.et
Fortress Biotech (NASDAQ: FBIO) reports 2026 director and auditor vote tallies - Stock Titan
Fortress Biotech Inc (FBIO) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Fortress Biotech Inc. (FBIO) Q4 2025 Earnings: EPS Misses Estimates on Higher R&D CostsCash Flow Report - dars.gov.et
Fortress Biotech StockSaturday deep dive on the business model - AD HOC NEWS
Mustang Bio Inc (MBIO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Fortress Biotech (FBIO) AGM 2026 Summary - Quartr
Fortress Biotech Inc Annual Shareholders Meeting Transcript - GuruFocus
Fortress Biotech Inc (FBIO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Fortress Biotech Inc. Q4 2025 Earnings: EPS Misses Estimates, Stock Rises Amid Strategic UpdateRevenue Miss Report - dars.gov.et
(FBIOP) Volatility Zones as Tactical Triggers - Stock Traders Daily
FBIOP Q4 2025 Earnings: Preferred Stock Reports Wider-than-Expected Loss Amid Narrowing Pipeline Progress - newsline.com
Fortress Biotech Preferred Stock (FBIOP) Edges Higher Before Resistance TestPut Support - newsline.com
Fortress Biotech Inc (FBIO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.44%
0.02%
자본화:
|
볼륨(24시간):